Q-omics provides the consensus-scored RBM4B profile across patient tissues and cancer cell-line models. RBM4B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RBM4B is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, RBM4B RNA expression shows 21,133 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where RBM4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM4B survival associations across molecular data types. RBM4B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM4B RNA expression–survival associations across cancer types. High RBM4B expression shows unfavorable associations in KICH, ACC, LIHC, DLBC and LUSC, but favorable associations in UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for RBM4B RNA expression.
This table summarizes RBM4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM4B shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and KIRC. The THCA box plot shows higher RBM4B RNA expression in normal versus tumor tissue (log2 FC = −0.943, t-test p < 0.001).
This table shows molecular features associated with RBM4B in patient tissues and cancer cell lines. In patient samples, RBM4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
